Every payer’s checklist is different. This week: Health-Related Quality of Life—how patient experience shapes coverage.

MARA Rating Insight: Since 2020, drugs averaging a 2.8 HRQoL score secured reimbursement far more often than those at 2.4, which faced higher rejection rates. That 0.4-point gap underscores how critical patient-centered outcomes have become in HTA decisions.

Did you know? At MARA Rating, we distill the evidence requirements of NICE (UK), G-BA/IQWiG (Germany) and ICER (US) into a straightforward A++ to C score—now across 350+ assets. Health-Related Quality of Life is the domain where your therapy proves its impact on symptoms, function and well-being MARA rating Methodology….

What Is Health-Related Quality of Life? Payers want to see that your treatment does more than move biomarkers—it enhances daily life:

• Patient-Reported Outcomes (PROs): Validated surveys on pain, mobility, fatigue, mental health.
• Utility Gains: Changes in generic measures (e.g. EQ-5D) that feed cost-effectiveness models.
• Symptom Burden Reduction: Quantifiable drops in key symptoms (e.g. attack frequency, attack severity).

Strong vs. Marginal Scores

• A++ / A+ / A (“Strong or above”): Demonstrates clear, statistically and clinically meaningful improvements in PROs—payers recognize real patient benefit and often award higher value ratings.
• B++ to C (“Marginal or below”): Shows inconsistent or modest quality-of-life gains—payers may question whether benefits justify cost, leading to tougher negotiations or restricted coverage.

Even a single-grade uptick can shift HTA verdicts from “added benefit unlikely” to “meaningful benefit confirmed.”

Actionable Tips by Role

• Market Access Professionals: Integrate PRO collection into every trial phase—select endpoints that resonate with both patients and payers, and ensure high completion rates.
• Venture Investors & Acquirers: Prioritize assets with published utility data—drugs that quantify EQ-5D gains translate directly into stronger cost-effectiveness profiles and clearer reimbursement pathways.
• Drug Developers: Embed generic QoL instruments (EQ-5D or SF-36) alongside disease-specific scales to demonstrate both nuanced patient impact and broad utility for economic modeling.

See Your Edge Our anonymized distributions across 350+ assets spotlight exactly where your HRQoL evidence stacks up—and where you risk a “no added benefit” outcome.

Do you know how your product scores? Visit mararating.com or send us a line.

#MarketAccess #HTA #EvidenceStrategy #HealthRelatedQualityOfLife #MARARating #MarketAccessScore